F. Chung (London, United Kingdom), K. Ohta (Tokyo, Japan)
Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial
M. Laviolette, I. Pavord, N. Thomson, R. Niven, G. Cox, P. Corris, K. Fan-Chung (Québec, Hamilton, Canada; Leicester, Glasgow, Manchester, Newcastle-upon-Tyne, London, United Kingdom)
|   |
Efficacy of high-dose leukocytaphereis using extracorporeal circulation through a large leukocyte-removal filter column in patients with refractory asthma
T. Ishizuka, A. Koike, M. Hatori, S. Matsuzaki, Y. Kamide, H. Aoki, T. Hisada, H. Tsurumaki, A. Ono, Y. Koga, K. Dobashi, K. Suzuki, M. Mori (Maebashi, Japan)
| |
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response
V. Norris, J. Bentley, S. Kent, M. Boyce, Z. Diamant, D. Singh, B. O‘Connor (Stevenage, London, Manchester, United Kingdom; Leiden, Netherlands)
| |
Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma
E. Piper, C. Brightling, R. Niven, C. Oh, R. Faggioni, K. Poon, D. She, C. Kell, R. May, G. Geba, N. Molfino (Gaithersburg, United States Of America; Leicester, Manchester, United Kingdom)
| |
Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels
N. A. Hanania, R. F. Lemanske, Jr., P. E. Korenblat, J. R. Arron, J. M. Harris, Z. Su, S. Mosesova, J. G. Matthews, M. V. Parsey, S. Bohen, M. M. Freemer (Houston, Madison, St. Louis, South San Francisco, Menlo Park, United States Of America)
| |
NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: The GLOW1 trial
A. D‘Urzo, G. Ferguson, C. Martin, Y. Lu, D. Banerji, T. Overend (ON, Canada; Livonia, East Hanover, United States Of America; Horsham, United Kingdom)
| |
Pleiotropic effects of add-on atorvastatin therapy during the treatment of COPD patients
R. Mroz, A. Tycinska, L. Minarowski, J. Bierla, P. Lisowski, B. Sobkowicz, E. Chyczewska, W. Musial, W. MacNee (Bialystok, Warsaw, Poland; Edinburgh, United Kingdom)
| |
Beta-blockers in chronic obstructive pulmonary disease – A retrospective cohort study
P. Short, D. Elder, P. Williamson, S. Lipworth, S. Schembri, B. Lipworth (Dundee, St. Andrews, Perth, United Kingdom)
| |